NIH/Industry Oncology Partnership Aims For Immunotherapy Biomarkers
Part of the Cancer Moonshot program, the five-year, $215 million research collaboration will be mostly funded by NIH with money from the 21st Century Cures Act.
You may also be interested in...
'Although sponsors have conventionally focused on the development of a drug, the strategy of pursuing site-agnostic indications must focus on both drug and biomarker development,' FDA's Richard Pazdur and colleagues write in the New England Journal of Medicine.
Accelerated approval for patients with microsatellite instability-high or mismatch repair deficient solid tumors is the first time the US FDA has granted an indication that does not specify the location of the tumor – a change precision medicine researchers have been eager to make.
NIH Director Collins and FDA Commissioner Califf discuss difficulties with ‘big science,’ ‘small crappy trials,’ and ‘data landlords.’